Up­dat­ed: Lil­ly boosts sales guid­ance by $2B, but GLP-1 sup­ply con­straints still a fo­cus

Eli Lil­ly is ex­pect­ing sup­ply dis­rup­tions for its block­buster weight loss and di­a­betes prod­ucts to con­tin­ue through the end of this year, ex­ec­u­tives told in­vestors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER